VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | SELECT-AML-1: tamibarotene with venetoclax and azacitidine in patients with RARA-positive AML

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explains the rationale and design of the SELECT-AML-1 trial (NCT04905407) evaluating the RARA agonist tamibarotene in combination with venetoclax and azacitidine in patients with RARA-positive acute myeloid leukemia (AML). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter